Interview: Positive data for Lynparza in pancreatic cancer

Country

United States

It is estimated that up to 7% of patients with pancreatic cancer have a mutation in the tumour suppressor genes BRCA1 and BRCA2, impairing the body's ability to repair damaged DNA and allowing tumours to grow. BRCA mutations also drive ovarian and breast cancers, but they can be particularly lethal in pancreatic tumours because this cancer is difficult to detect at an early stage.